UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000023612
Receipt No. R000027191
Scientific Title Japanese Type 1 diabetes data-basE
Date of disclosure of the study information 2016/08/12
Last modified on 2016/08/12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Japanese Type 1 diabetes data-basE
Acronym TIDE-J
Scientific Title Japanese Type 1 diabetes data-basE
Scientific Title:Acronym TIDE-J
Region
Japan

Condition
Condition Type 1 diabetes
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information YES

Objectives
Narrative objectives1 Japanese type 1 diabetes is classified into 3 subclasses: acute-onset type 1 diabetes, fulminant type 1 diabetes and slowly progressive type 1 diabetes. Our aim is to establish the comprehensive database of genomic and clinical information based on sub-classification of type 1 diabetes and to apply the database for development of new diagnostic markers, elucidation of etiological mechanism, prediction of type 1 diabetes and investigation of optimal treatments.
Basic objectives2 Others
Basic objectives -Others To clarify the genomic and clinical characteristics of 3 subclasses of Japanese type 1 diabetes.
Trial characteristics_1 Others
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes 1)To clarify the natural histories of 3 subclasses of Japanese type 1 diabetes and to establish the genomic and serum library as the basal data for intervention studie.
2)To analyze the integrated information of the genetic data and longitudinal clinical and biochemical data based on the established database.
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
16 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients with type 1 diabetes meeting the criteria shown as below.
1) Less than 5 years after the onset of diabetes
2) Positive for any pancreatic islet related autoantibodies and/or less than 1.0 ng/ml of C-peptide in fasting serum at diagnosis
Key exclusion criteria Not applicable
Target sample size 250

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hiroshi Kajio
Organization National Center for Global Health and Medicine Hospital
Division name Department of Diabetes, Endocrinology and Metabolism
Zip code
Address 1-21-1, Toyama, Shinjuku-ku, Tokyo, Japan
TEL +81-3-3202-7181
Email hkajio@hosp.ncgm.go.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hiroshi Kajio
Organization National Center for Global Health and Medicine Hospital
Division name Department of Diabetes, Endocrinology and Metabolism
Zip code
Address 1-21-1, Toyama, Shinjuku-ku, Tokyo, Japan
TEL +81-3-3202-7181
Homepage URL
Email hkajio@hosp.ncgm.go.jp

Sponsor
Institute National Center for Global Health and Medicine
Institute
Department

Funding Source
Organization National Center for Global Health and Medicine
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 国立国際医療研究センター(東京都、千葉県)、大阪医科大学(大阪府)、山梨大学(山梨県)、近畿大学(大阪府)、大阪大学(大阪府)、埼玉医科大学(埼玉県)、愛媛大学(愛媛県)、長崎大学(長崎県)、新古賀病院(福岡県)、岩手医科大学(岩手県)、済生会中央病院(東京都)、神戸大学(兵庫県)、冲中記念成人病研究所(東京都)、岩手県立大学(岩手県)、昭和大学(東京都)、国際医療福祉大学(栃木県)

Other administrative information
Date of disclosure of the study information
2016 Year 08 Month 12 Day

Related information
URL releasing protocol
Publication of results Partially published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
At 59th scientific annual meeting of Japan Diabetes Society, we gave a tentative report on the characteristics of insulin secretion, pancreatic islet related autoantibidies and genome in 3 subclasses of Japanese type 1 diabetes based on the data from the subjects recruited until then. 
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2010 Year 12 Month 17 Day
Date of IRB
Anticipated trial start date
2011 Year 07 Month 11 Day
Last follow-up date
2021 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
2023 Year 03 Month 31 Day

Other
Other related information Clinical check and blood sampling are performed regularly once a year. Genome sampling is performed at entry.
1) Check points at entry
Back ground: age at onset, sex, body length, body weight, blood pressure, duration of diabetes, family history, past history, diabetic complications (retinopathy, nephropathy, neuropathy), symptoms at onset, accompany of other autoimmune diseases, pregnancy before onset of diabetes, signs of abdominal abnormalities (abdominal echogram, abdominal CT, MRI), sign of pancreatic abnormality, blood gas analysis at onset, parameters of carbohydrate metabolism: plasma glucose level, HbA1c(NGSP), glycoalbumin, urine ketone body, serum ketone body, parameters of insulin secretion: fasting blood C-peptide level, exocrine pancreatic enzymes (amylase, elastase 1, lipase), islet associated autoantibodies (anti-GAD antibody, anti-IA-2 antibody, IAA(within 2 weeks after beginning of treatment), anti-ZnT8 antibody, thyroid associated autoantibodies (anti-thyroglobulin antibody, anti-TPO antibody, anti-TSH receptor antibody), HLA typing (A, B, C, DRB1-DQA1-DQB1), other genetic analyses (insulin, CTLA4, PTPN22, IL2RA, SUMO-4, vitamin D receptor and et al.), treatment, insulin for one day (dose, types, frequency), type of type 1 diabetes, classification of type 1 diabetes (day at diagnosis)
2) Check points (every year)
body length, body weight, blood pressure, diabetic complications (retinopathy, nephropathy, neuropathy) , parameters of carbohydrate metabolism: plasma glucose level, HbA1c(NGSP), parameters of insulin secretion: fasting blood C-peptide level (5ml serum at fasting is preserved), islet associated autoantibodies (anti-GAD antibody, anti-IA-2 antibody), treatment, insulin for one day (dose, types, frequency), medicines used with insulin

Management information
Registered date
2016 Year 08 Month 12 Day
Last modified on
2016 Year 08 Month 12 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027191

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.